Phase 2/3 Study of IGSC, 20% in PIDD

Main Inclusion Criteria:

- Documented diagnosis of a form of primary humoral immunodeficiency involving defective
antibody formation and requiring gammaglobulin replacement as defined according to the
IUIS Scientific Committee, 2011 and by diagnostic criteria according to Conley et al.
(1999). The diagnosis must be confirmed by the Medical Director prior to first
treatment with the investigational product (IP) in the study.

- Participant is 2 years or older at the time of screening, and has a minimum body
weight of 13 kg.

- Written informed consent has been obtained from either the participant or the
participant's legally authorized representative prior to any study-related procedures
and study product administration

- Participant has been receiving a stable monthly equivalent dose of IgG at an average
minimum dose equivalent to 300 mg/kg bodyweight (BW)/4 weeks and a maximum dose
equivalent to 1.0 gram/kg BW/4 weeks, for a minimum of 12 weeks prior to first
treatment with the IP in the study.

- Serum trough level of IgG > 500 mg/dL at screening

- Participant is willing and able to comply with the requirements of the protocol

Main Exclusion Criteria:

- Participant has known history of or is positive at screening for one or more of the
following: hepatitis B surface antigen (HBsAg), polymerase chain reaction (PCR) for
Hepatitis C virus(HCV), PCR for human immunodeficiency virus (HIV) Type 1/2

- Abnormal laboratory values at screening meeting any one of the following criteria
(abnormal tests may be repeated once to determine if they are persistent):

- Persistent alanine aminotransferase (ALT) and aspartate amino transferase(AST) >
2.5 times the upper limit of normal for the testing laboratory

- Persistent severe neutropenia (defined as an absolute neutrophil count [ANC]
≤500/mm^3)

- Creatinine clearance (CLcr) value that is < 60% of normal for age and gender either
measured, or calculated according to the Cockcroft-Gault formula

- Malignancy (other than adequately treated basal cell or squamous cell carcinoma of the
skin or carcinoma in situ of the cervix), unless the disease-free period prior to
screening exceeds 5 years

- Participant is receiving anti-coagulation therapy (low dose aspirin at ≤325 mg/day is
permitted) or has a history of thrombotic episodes (including deep vein thrombosis,
myocardial infarction, cerebrovascular accident, pulmonary embolism) or sickle cell
disease with crisis within 12 months prior to screening or a history of thrombophilia

- Abnormal protein loss (protein losing enteropathy, nephrotic syndrome)

- Anemia that would preclude phlebotomy for laboratory studies according to standard
practice at the site

- Acute serious bacterial infection within 3 months prior to screening

- Ongoing history of hypersensitivity or persistent reactions (urticaria, breathing
difficulty, severe hypotension, or anaphylaxis) following intravenous immunoglobulin,
subcutaneous immunoglobulin, and/or Immune Serum Globulin (ISG) infusions

- Severe immunoglobulin A (IgA) deficiency (less than 0.07g/L) with known anti-IgA
antibodies and a history of hypersensitivity

- Participant is on continuous systemic antibacterial antibiotics at doses sufficient to
treat or prevent bacterial infections, and, in the opinion of the investigator, cannot
stop these for the duration of the study without putting the patient at risk of
increased infections

- Participant has active infection and is receiving antibiotic therapy for the treatment
of infection at the time of screening

- Bleeding disorder or thrombocytopenia with a platelet count less than 20,000/μL, or
who, in the opinion of the investigator, would be at significant risk of increased
bleeding or bruising as a result of subcutaneous therapy

- Total protein > 9 g/dL or myeloma or macroglobulinemia (IgM) or paraproteinemia

- Severe dermatitis that would preclude adequate sites for safe product administration

- Women of childbearing potential meeting any one of the following criteria:

- Participant presents with a positive pregnancy test

- Participant is breast feeding

- Participant intends to begin nursing during the course of the study

- Participant does not agree to employ adequate birth-control measures (e.g.
intrauterine device, diaphragm or condom [for male partner] with spermicidal
jelly or foam, or birth control pills/patches) throughout the course of the study

- Participation in another clinical study and exposure to an investigational product or
device within 30 days prior to study enrollment (exception: treatment in a previous
Baxter immunoglobulin study)

- Participant is scheduled to participate in another (non-Baxter) non-observational
(interventional) clinical study involving an investigational product or device during
the course of the study